Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
Recruiting · NCT05597709 · Observational (researchers observe without assigning treatment) · Lead sponsor: Wuxi Hisky Medical Technology Co Ltd
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.
Who can take part
Inclusion criteria
- Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes
- UAP were measured based on iLivTouch
- Willing to attend this study and able to provide the written informed consent.
Exclusion criteria
- Other types of diabetes
- Patients unable to receive regular follow-up
Where it is running
1 location listed.
- Zhongda Hospital, Medical School, Southeast University - Nanjing, Jiangsu, China